SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Clinical trial NCT06123494 · RECRUITING
Trial details
- NCT number
- NCT06123494
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-09
- Primary completion
- 2027-06-30
- Enrollment
- 360
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.